Roth/ MKM initiates coverage for Rapid Micro Biosystems stock

Published on 10/02/2026 at 04:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 8.10 million, up 11.00 percent year over year. Rapid Micro Biosystems stock has a USD 41.7 million market cap.

RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems (ISIN US75340L1044) drew a Buy rating as Roth/MKM initiated coverage on September 29, 2026, with a USD 3.00 price target, according to Investing.com. The call arrives as the company works to scale its Growth Direct automation platform while improving profitability.

Analyst target meets operating progress

Rapid Micro Biosystems reported USD 8.1 million of total revenue in the second quarter of 2026, an 11.00 percent increase from the second quarter of 2025. The company also said it placed four systems and completed nine validations during the quarter.

The same release identified the 200th Growth Direct system placed globally as a milestone. That installed base gives the company a commercial footprint, but the financial profile remains demanding: standardized financial data show a USD 12.923 million net loss and diluted earnings per share of minus USD 0.27 for the second quarter of 2026.

Margins and installed systems matter

Rapid Micro Biosystems reported a 15.00 percent gross margin in the second quarter of 2026, compared with 5.00 percent in the first quarter, based on standardized financial data. The improvement is important because the company generated negative operating cash flow of USD 12.702 million in the same quarter.

At the September 24, 2026 Small-Cap Virtual Conference, management described 169 validated systems and 200 systems placed globally, while presenting margin expansion as a central operating objective, according to Investing.com. The contrast between growing deployment and continuing losses defines the risk and opportunity in the current setup.

Market value stays below yearly high

Rapid Micro Biosystems had a market capitalization of USD 41.7 million and a 52-week range of USD 0.92 to USD 4.94 as of October 1, 2026. The lower end of that range matches the latest structured quote, while the yearly high remains more than five times the low, underscoring the stock's volatility.

The company operates on Nasdaq under ticker RPID and supplies automated microbial quality-control systems for pharmaceutical manufacturing. Its Growth Direct platform combines instruments, disposable components and software, linking recurring consumables with the installed equipment base.